benralizumab + benralizumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Chronic Rhinosinusitis
Conditions
Eosinophilic Chronic Rhinosinusitis
Trial Timeline
Jun 1, 2016 → Mar 27, 2017
NCT ID
NCT02772419About benralizumab + benralizumab + Placebo
benralizumab + benralizumab + Placebo is a phase 2 stage product being developed by Kyowa Kirin for Eosinophilic Chronic Rhinosinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02772419. Target conditions include Eosinophilic Chronic Rhinosinusitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02772419 | Phase 2 | Completed |
Competing Products
20 competing products in Eosinophilic Chronic Rhinosinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| SHR-1703 + SHR-1703 Placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Esomeprazole + Budesonide | AstraZeneca | Phase 2/3 | 65 |
| Tezepelumab + Tezepelumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Approved | 85 |
| Cohort | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Matching placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab Prefilled Syringe | AstraZeneca | Approved | 85 |
| benralizumab | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 2/3 | 65 |
| inhaled/swallowed budesonide + viscous/swallowed budesonide | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + 129 Xenon | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |